Drug intelligence / Profile preview

microRNA-17-92-enriched exosomes

Development stage: Preclinical
Modality: RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

MicroRNA-17-92-enriched exosomes are an experimental biologic therapy consisting of exosomes (small extracellular vesicles) derived from mesenchymal stromal cells (MSCs) that have been genetically engineered to overexpress the miR-17-92 microRNA cluster. This cluster contains six individual microRNAs: miR-17, miR-18a, miR-19a, miR-19b, miR-20a, and miR-92a. The therapy is designed to treat neurological conditions such as stroke, traumatic brain injury, and spinal cord injury by delivering these microRNAs to target tissues. The primary mechanism of action involves the suppression of phosphatase and tensin homolog (PTEN), which subsequently activates the PI3K/Akt/mTOR signaling pathway. This activation promotes neuroplasticity, neurogenesis, and oligodendrogenesis while reducing neuroinflammation, ultimately improving functional recovery in preclinical models. Currently, this therapy remains in the research and preclinical development stage without a commercial developer.

Other names: miR-17-92-enriched MSC-exosomesmiR17-92-enriched MSC-exosomesmiR 17-92-enriched MSC-exosomesmiR-17-92 cluster-enriched exosomesmiR17-92 cluster-enriched exosomesmiR 17-92 cluster-enriched exosomesmesenchymal stromal cell-derived miR-17-92-enriched exosomes

Targets

IKZF4 (Ikaros family zinc finger protein 4)PTEN (Phosphatase and tensin homolog deleted on chromosome ten)

Beyond the preview

Go deeper on microRNA-17-92-enriched exosomes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on microRNA-17-92-enriched exosomes.

Explore the full profile